Deleterious Anti-Inflammatory Macrophage Recruitment in Early Post-Infarction Phase: Unraveling the IL-6/MCP-1/STAT3 Axis.

IL-6 MCP-1 STAT3 inflammation macrophages myocardial infarction

Journal

JACC. Basic to translational science
ISSN: 2452-302X
Titre abrégé: JACC Basic Transl Sci
Pays: United States
ID NLM: 101677259

Informations de publication

Date de publication:
May 2024
Historique:
received: 01 11 2023
revised: 19 01 2024
accepted: 19 01 2024
medline: 10 7 2024
pubmed: 10 7 2024
entrez: 10 7 2024
Statut: epublish

Résumé

Using a translational approach with an ST-segment myocardial infarction (STEMI) cohort and mouse model of myocardial infarction, we highlighted the role of the secreted IL-6 and MCP-1 cytokines and the STAT3 pathway in heart macrophage recruitment and activation. Cardiac myocytes secrete IL-6 and MCP-1 in response to hypoxic stress, leading to a recruitment and/or polarization of anti-inflammatory macrophages via the STAT3 pathway. In our preclinical model of myocardial infarction, neutralization of IL-6 and MCP-1 or STAT3 pathway reduced infarct size. Together, our data demonstrate that anti-inflammatory macrophages can be deleterious in the acute phase of STEMI.

Identifiants

pubmed: 38984050
doi: 10.1016/j.jacbts.2024.01.019
pii: S2452-302X(24)00053-6
pmc: PMC11228110
doi:

Types de publication

Journal Article

Langues

eng

Pagination

593-604

Informations de copyright

© 2024 The Authors.

Déclaration de conflit d'intérêts

This work was supported by “Federation Française de Cardiologie,” and LABEX CORTEX (ANR-11-LABX-0042) and FRM (FD202012010540). The authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Auteurs

Alexandre Paccalet (A)

Laboratoire CarMeN-IRIS Team, INSERM, INRA, Université Claude Bernard Lyon-1, INSA-Lyon, University of Lyon, Bron, France.

Sally Badawi (S)

Laboratoire CarMeN-IRIS Team, INSERM, INRA, Université Claude Bernard Lyon-1, INSA-Lyon, University of Lyon, Bron, France.

Bruno Pillot (B)

Laboratoire CarMeN-IRIS Team, INSERM, INRA, Université Claude Bernard Lyon-1, INSA-Lyon, University of Lyon, Bron, France.

Lionel Augeul (L)

Laboratoire CarMeN-IRIS Team, INSERM, INRA, Université Claude Bernard Lyon-1, INSA-Lyon, University of Lyon, Bron, France.

Laura Mechtouff (L)

Laboratoire CarMeN-IRIS Team, INSERM, INRA, Université Claude Bernard Lyon-1, INSA-Lyon, University of Lyon, Bron, France.

Zeina Harhous (Z)

Laboratoire CarMeN-IRIS Team, INSERM, INRA, Université Claude Bernard Lyon-1, INSA-Lyon, University of Lyon, Bron, France.

Yves Gouriou (Y)

Laboratoire CarMeN-IRIS Team, INSERM, INRA, Université Claude Bernard Lyon-1, INSA-Lyon, University of Lyon, Bron, France.

Mélanie Paillard (M)

Laboratoire CarMeN-IRIS Team, INSERM, INRA, Université Claude Bernard Lyon-1, INSA-Lyon, University of Lyon, Bron, France.

Marine Breuilly (M)

CIQLE, LyMIC, LABEX CORTEX, Université Claude Bernard Lyon 1, Structure Fédérative de Recherche santé Lyon-Est CNRS UAR3453/Inserm US7, Lyon, France.

Camille Amaz (C)

Centre d'Investigation Clinique de Lyon (CIC 1407 Inserm), Hospices Civils de Lyon, Lyon, France.

Yvonne Varillon (Y)

Centre d'Investigation Clinique de Lyon (CIC 1407 Inserm), Hospices Civils de Lyon, Lyon, France.

Simon Leboube (S)

Laboratoire CarMeN-IRIS Team, INSERM, INRA, Université Claude Bernard Lyon-1, INSA-Lyon, University of Lyon, Bron, France.

Camille Brun (C)

Laboratoire CarMeN-IRIS Team, INSERM, INRA, Université Claude Bernard Lyon-1, INSA-Lyon, University of Lyon, Bron, France.

Cyril Prieur (C)

Centre d'Investigation Clinique de Lyon (CIC 1407 Inserm), Hospices Civils de Lyon, Lyon, France.

Gilles Rioufol (G)

Centre d'Investigation Clinique de Lyon (CIC 1407 Inserm), Hospices Civils de Lyon, Lyon, France.

Nathan Mewton (N)

Laboratoire CarMeN-IRIS Team, INSERM, INRA, Université Claude Bernard Lyon-1, INSA-Lyon, University of Lyon, Bron, France.
Centre d'Investigation Clinique de Lyon (CIC 1407 Inserm), Hospices Civils de Lyon, Lyon, France.
Intensive Cardiological Care Division, Louis Pradel Hospital, Hospices Civils de Lyon, Lyon, Bron, France.

Michel Ovize (M)

Laboratoire CarMeN-IRIS Team, INSERM, INRA, Université Claude Bernard Lyon-1, INSA-Lyon, University of Lyon, Bron, France.

Gabriel Bidaux (G)

Laboratoire CarMeN-IRIS Team, INSERM, INRA, Université Claude Bernard Lyon-1, INSA-Lyon, University of Lyon, Bron, France.

Thomas Bochaton (T)

Laboratoire CarMeN-IRIS Team, INSERM, INRA, Université Claude Bernard Lyon-1, INSA-Lyon, University of Lyon, Bron, France.
Centre d'Investigation Clinique de Lyon (CIC 1407 Inserm), Hospices Civils de Lyon, Lyon, France.
University Claude Bernard Lyon 1, Lyon, France.

Claire Crola Da Silva (C)

Laboratoire CarMeN-IRIS Team, INSERM, INRA, Université Claude Bernard Lyon-1, INSA-Lyon, University of Lyon, Bron, France.

Classifications MeSH